Screener
Relmada Therapeutics, Inc. RLMD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
| Unrealized (loss)/gain on short-term investments | (540,097) | 155,731 |
| Total other income, net | 409,798 | 658,970 |
| Net loss | $(19,051,956) | $(17,559,465) |
| Loss per common share – basic and diluted | $(0.22) | $(0.58) |
| Weighted average number of common shares outstanding – basic and diluted | 86,596,873 | 30,408,890 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s EPS (diluted)?
- Relmada Therapeutics, Inc. (RLMD) reported EPS (diluted) of -$0.22 in Q1 2026.
- How has Relmada Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Relmada Therapeutics, Inc.'s EPS (diluted) increased by 62.1% year-over-year, from -$0.58 to -$0.22.
- What is the long-term trend for Relmada Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s EPS (diluted) has grown at a -32.6% compound annual growth rate (CAGR), from -$7.14 to -$1.47.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Relmada Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude